Health Technology Assessment and Its Use in Drug Policy in Malaysia

Asrul Akmal Shafie, Haarathi Chandriah, Yee Vern Yong, Sharifa Ezat Wan Puteh

Research output: Contribution to journalArticle

Abstract

Objective: To describe the process and role of health technology assessment (HTA) in the context of drug policy in Malaysia. Methods: We summarized the HTA process through review of documents and reports available in the public domain combined with the authors' experience. Results: Health technology assessment plays an integral part in prioritizing treatment in public health facilities in Malaysia, particularly for the Ministry of Health Medicines Formulary (MOHMF). The MOHMF is the reference list of drugs allowed to be prescribed in the Ministry of Health (MOH) facilities. There are 2 organizations within the MOH that conduct HTA as their core activities, namely the Malaysian Health Technology Assessment Section and the Formulary Management Branch of Pharmacy Practice & Development Division. The assessment of pharmaceuticals for the purpose of listing medicines into the MOHMF is under the purview of the Formulary Management Branch. The evidence-based assessment focuses on safety, efficacy, effectiveness, and budget impact of the drug. Cost-effectiveness evidence is currently not mandatory but is of interest to the decision makers. The assessment outcomes are considered by the MOH Medicines List Review Panel for formulary decisions. Conclusions: Health technology assessment has supported formulary decisions in MOH. Evidence generation needs to progress beyond efficacy or effectiveness, safety, and budget impact to incorporate cost-effectiveness. Nevertheless, there are challenges to be met to achieve this. The impact of the HTA process is currently unknown and is yet to be evaluated formally.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalValue in Health Regional Issues
Volume18
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Formularies
Biomedical Technology Assessment
Malaysia
Pharmaceutical Preparations
Health
Health Facilities
Budgets
Cost-Benefit Analysis
Public Facilities
Safety
Public Sector
Drug policy
Health technology assessment
Public Health
Outcome Assessment (Health Care)
Medicine
Organizations

Keywords

  • drug pricing
  • formulary listing
  • health technology assessment
  • Malaysia

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Health Technology Assessment and Its Use in Drug Policy in Malaysia. / Shafie, Asrul Akmal; Chandriah, Haarathi; Yong, Yee Vern; Wan Puteh, Sharifa Ezat.

In: Value in Health Regional Issues, Vol. 18, 01.05.2019, p. 145-150.

Research output: Contribution to journalArticle

Shafie, Asrul Akmal ; Chandriah, Haarathi ; Yong, Yee Vern ; Wan Puteh, Sharifa Ezat. / Health Technology Assessment and Its Use in Drug Policy in Malaysia. In: Value in Health Regional Issues. 2019 ; Vol. 18. pp. 145-150.
@article{6e4782dad7aa4c438842ccffb2cee358,
title = "Health Technology Assessment and Its Use in Drug Policy in Malaysia",
abstract = "Objective: To describe the process and role of health technology assessment (HTA) in the context of drug policy in Malaysia. Methods: We summarized the HTA process through review of documents and reports available in the public domain combined with the authors' experience. Results: Health technology assessment plays an integral part in prioritizing treatment in public health facilities in Malaysia, particularly for the Ministry of Health Medicines Formulary (MOHMF). The MOHMF is the reference list of drugs allowed to be prescribed in the Ministry of Health (MOH) facilities. There are 2 organizations within the MOH that conduct HTA as their core activities, namely the Malaysian Health Technology Assessment Section and the Formulary Management Branch of Pharmacy Practice & Development Division. The assessment of pharmaceuticals for the purpose of listing medicines into the MOHMF is under the purview of the Formulary Management Branch. The evidence-based assessment focuses on safety, efficacy, effectiveness, and budget impact of the drug. Cost-effectiveness evidence is currently not mandatory but is of interest to the decision makers. The assessment outcomes are considered by the MOH Medicines List Review Panel for formulary decisions. Conclusions: Health technology assessment has supported formulary decisions in MOH. Evidence generation needs to progress beyond efficacy or effectiveness, safety, and budget impact to incorporate cost-effectiveness. Nevertheless, there are challenges to be met to achieve this. The impact of the HTA process is currently unknown and is yet to be evaluated formally.",
keywords = "drug pricing, formulary listing, health technology assessment, Malaysia",
author = "Shafie, {Asrul Akmal} and Haarathi Chandriah and Yong, {Yee Vern} and {Wan Puteh}, {Sharifa Ezat}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.vhri.2019.03.003",
language = "English",
volume = "18",
pages = "145--150",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Health Technology Assessment and Its Use in Drug Policy in Malaysia

AU - Shafie, Asrul Akmal

AU - Chandriah, Haarathi

AU - Yong, Yee Vern

AU - Wan Puteh, Sharifa Ezat

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Objective: To describe the process and role of health technology assessment (HTA) in the context of drug policy in Malaysia. Methods: We summarized the HTA process through review of documents and reports available in the public domain combined with the authors' experience. Results: Health technology assessment plays an integral part in prioritizing treatment in public health facilities in Malaysia, particularly for the Ministry of Health Medicines Formulary (MOHMF). The MOHMF is the reference list of drugs allowed to be prescribed in the Ministry of Health (MOH) facilities. There are 2 organizations within the MOH that conduct HTA as their core activities, namely the Malaysian Health Technology Assessment Section and the Formulary Management Branch of Pharmacy Practice & Development Division. The assessment of pharmaceuticals for the purpose of listing medicines into the MOHMF is under the purview of the Formulary Management Branch. The evidence-based assessment focuses on safety, efficacy, effectiveness, and budget impact of the drug. Cost-effectiveness evidence is currently not mandatory but is of interest to the decision makers. The assessment outcomes are considered by the MOH Medicines List Review Panel for formulary decisions. Conclusions: Health technology assessment has supported formulary decisions in MOH. Evidence generation needs to progress beyond efficacy or effectiveness, safety, and budget impact to incorporate cost-effectiveness. Nevertheless, there are challenges to be met to achieve this. The impact of the HTA process is currently unknown and is yet to be evaluated formally.

AB - Objective: To describe the process and role of health technology assessment (HTA) in the context of drug policy in Malaysia. Methods: We summarized the HTA process through review of documents and reports available in the public domain combined with the authors' experience. Results: Health technology assessment plays an integral part in prioritizing treatment in public health facilities in Malaysia, particularly for the Ministry of Health Medicines Formulary (MOHMF). The MOHMF is the reference list of drugs allowed to be prescribed in the Ministry of Health (MOH) facilities. There are 2 organizations within the MOH that conduct HTA as their core activities, namely the Malaysian Health Technology Assessment Section and the Formulary Management Branch of Pharmacy Practice & Development Division. The assessment of pharmaceuticals for the purpose of listing medicines into the MOHMF is under the purview of the Formulary Management Branch. The evidence-based assessment focuses on safety, efficacy, effectiveness, and budget impact of the drug. Cost-effectiveness evidence is currently not mandatory but is of interest to the decision makers. The assessment outcomes are considered by the MOH Medicines List Review Panel for formulary decisions. Conclusions: Health technology assessment has supported formulary decisions in MOH. Evidence generation needs to progress beyond efficacy or effectiveness, safety, and budget impact to incorporate cost-effectiveness. Nevertheless, there are challenges to be met to achieve this. The impact of the HTA process is currently unknown and is yet to be evaluated formally.

KW - drug pricing

KW - formulary listing

KW - health technology assessment

KW - Malaysia

UR - http://www.scopus.com/inward/record.url?scp=85065424659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065424659&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2019.03.003

DO - 10.1016/j.vhri.2019.03.003

M3 - Article

C2 - 31082794

AN - SCOPUS:85065424659

VL - 18

SP - 145

EP - 150

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -